Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · HIKAL

HIKAL LTD.

HealthcarePharmaceuticals & Biotechnology₹2754 cr market cap
₹222.06 ▼ -0.49% today As of 19 Nov 2026
52-week low ₹147.0852-week high ₹256.15

-12.9% from the 52-week high · +51.7% above the low

Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,142 full-time employees. The firm operates through two segments: pharmaceuticals and crop protection. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. The Company’s products and services include gabapentin; thiabendazole, and diuron contract development and custom manufacturing of intermediates; application programming interface (APIs); and artificial intelligence (AI’s). The firm supplies its products to customers across the globe in the United States, Japan, Europe, Canada, Southeast Asia, Latin American, India and RoW.

The short version. HIKAL LTD. reported revenue of ₹434 crore for Sep 2026, up 36.5% from a year earlier. Net profit was ₹-6 crore. Return on equity was -4.1% in Mar 2026. Promoter holding was 68.85% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

HIKAL LTD. trades 12.9% below its 52-week high and 51.7% above its 52-week low.

Change over period: —

1M+2.7%
3M+4.2%
6M+9.0%
1Y-2.5%

2 · The business

Is it growing?

Sales, year on year+36.5%

Sep 2026 revenue of ₹434 cr.

Net margin-1.4%

9.6 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue434403519494318380552448
Net profit-6-714-6-35-225017
Net margin %-1.4-1.82.8-1.2-11.0-5.99.13.8
EPS (₹)-0.49-0.61.17-0.48-2.83-1.824.071.39

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue17131860178520231943172015071590
Net profit-4991707816113384103
Net margin %-2.84.93.93.98.37.75.66.5
EPS (₹)-3.967.365.646.3613.0210.86.858.36

3 · The quality

How well does it turn capital into profit?

Return on equity was -4.1% in Mar 2026; debt to equity is 0.57.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %-4.17.25.96.9
Return on capital %-1.011.48.88.9
EBITDA margin %8.617.915.112.9
Net margin %-2.84.93.93.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-5.3%-0.0%
Profit CAGR——
Debt to equity0.57
Interest cover-0.3x
Current ratio1.30

4 · The owners

Who holds it, and are they adding?

Promoter holding68.85%

Unchanged over 8 quarters.

Foreign institutions1.27%

Down 4.79 pts over 8 quarters.

Domestic institutions5.32%

Up 1.84 pts over 8 quarters.

Mutual fund schemes4

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter68.8568.8568.8568.8568.8568.8568.8568.850.0
FII6.065.695.364.232.31.430.991.27-4.79
DII3.483.84.025.167.057.27.245.32+1.84
Public21.6121.6621.7721.7621.7922.5222.9324.56+2.95

Mutual fund holdings · Oct 2026

4 schemes hold this stock

4 the month before.

  • ICICI Prudential Healthcare Fund0.89% of NAV
  • TATA SMALL CAP FUND0.59% of NAV
  • Motilal Oswal BSE Healthcare ETF0.05% of NAV
  • Bandhan BSE Healthcare Index Fund0.05% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for HIKAL LTD. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about HIKAL LTD.

What is the HIKAL LTD. share price?

HIKAL LTD. (HIKAL) last closed at ₹222.06, down 0.49% on the day. Its 52-week range is ₹147.08 to ₹256.15.

What is the market cap of HIKAL LTD.?

HIKAL LTD. has a market capitalisation of about ₹2,754 crore.

How are HIKAL LTD.'s latest results?

HIKAL LTD. reported revenue of ₹434 crore for Sep 2026, up 36.5% from a year earlier. Net profit was ₹-6 crore. Return on equity was -4.1% in Mar 2026. Promoter holding was 68.85% in Sep 2026, up 0.00 points over 8 quarters.

Who owns HIKAL LTD.?

As of Sep 2026, shareholding was: Promoter 68.85%, FII 1.27%, DII 5.32%, Public 24.56%.

How many mutual funds hold HIKAL LTD.?

4 mutual fund schemes held HIKAL LTD. in October 2026. That compares with 4 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 17 Feb 2026 · Interim Dividend - Rs. 0.2
  • 02 Sep 2025 · Final Dividend - Rs. 0.8
  • 07 Feb 2025 · Interim Dividend - Rs. 0.6
  • 04 Sep 2024 · Final Dividend - Rs. 0.6
  • 20 Feb 2024 · Interim Dividend - Rs. 0.6
  • 18 Sep 2023 · Final Dividend - Rs. 0.6

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.